Utilizing next-generation sequencing in the management of multiple myeloma

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

(2017) Cristina Jiménez et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

(2017) J Martinez-Lopez et al.   LEUKEMIA

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

(2016) N. Weinhold et al.   BLOOD

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

(2016) K. M. Kortum et al.   BLOOD

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

(2016) M. S. Raab et al.   BLOOD

Primary Plasma Cell Leukemia: Identity Card 2016

(2016) Pellegrino Musto et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation

(2016) Nicola Amodio et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

(2016) S Mithraprabhu et al.   LEUKEMIA

Identification of neutral tumor evolution across cancer types

(2016) Marc J Williams et al.   NATURE GENETICS

Genomic complexity of multiple myeloma and its clinical implications

(2016) Salomon Manier et al.   Nature Reviews Clinical Oncology

FAM46 proteins are novel eukaryotic non-canonical poly(A) polymerases

(2016) Krzysztof Kuchta et al.   NUCLEIC ACIDS RESEARCH

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution

(2016) J. G. Lohr et al.   Science Translational Medicine

Primary plasma cell leukemia 2.0: advances in biology and clinical management

(2016) Antonino Neri et al.   Expert Review of Hematology

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

(2016) K M Kortuem et al.   Blood Cancer Journal

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

(2016) N Bolli et al.   Blood Cancer Journal

Genetics of multiple myeloma: another heterogeneity level?

(2015) J. Corre et al.   BLOOD

Compendium ofFAM46Cgene mutations in plasma cell dyscrasias

(2015) Marzia Barbieri et al.   BRITISH JOURNAL OF HAEMATOLOGY

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

(2015) B. Paiva et al.   CLINICAL CANCER RESEARCH

Assessment of minimal residual disease in myeloma and the need for a consensus approach

(2015) Andy C. Rawstron et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance

(2015) Hisao Nagoshi et al.   GENES CHROMOSOMES & CANCER

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma

(2015) Daniela Drandi et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

N-of-1 trials in oncology

(2015) Laurence Collette et al.   LANCET ONCOLOGY

Inhibiting MEK in MAPK pathway-activated myeloma

(2015) C J Heuck et al.   LEUKEMIA

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

(2015) A K Mitra et al.   LEUKEMIA

Personalized medicine: Time for one-person trials

(2015) Nicholas J. Schork   NATURE

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

(2015) Sham Mailankody et al.   Nature Reviews Clinical Oncology

The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA

(2015) Simona Segalla et al.   NUCLEIC ACIDS RESEARCH

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

(2015) Brian A. Walker et al.   Nature Communications

Epigenomic evolution in diffuse large B-cell lymphomas

(2015) Heng Pan et al.   Nature Communications

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation

(2015) Marta Lionetti et al.   Oncotarget

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns

(2015) Ingrid Cifola et al.   Oncotarget

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias

(2015) Marta Lionetti et al.   Oncotarget

Differential and limited expression of mutant alleles in multiple myeloma

(2014) N. U. Rashid et al.   BLOOD

HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse

(2014) M. F. Martelli et al.   BLOOD

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in -17p high risk disease

(2014) Klaus M. Kortüm et al.   BRITISH JOURNAL OF HAEMATOLOGY

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma

(2014) Annamaria Brioli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma

(2014) J.P. Sharman et al.   Clinical Lymphoma Myeloma & Leukemia

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

(2014) L Melchor et al.   LEUKEMIA

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

(2013) G. Mulligan et al.   BLOOD

Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma

(2013) Nicola Amodio et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

(2013) B A Walker et al.   LEUKEMIA

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

(2013) M Ladetto et al.   LEUKEMIA

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia

(2013) A C Logan et al.   LEUKEMIA

IMWG consensus on risk stratification in multiple myeloma

(2013) W J Chng et al.   LEUKEMIA

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target

(2013) R. Tomecki et al.   NUCLEIC ACIDS RESEARCH

Targeting the BRAF V600E Mutation in Multiple Myeloma

(2013) M. Andrulis et al.   Cancer Discovery

Darwinian evolution and tiding clones in multiple myeloma

(2012) N. J. Bahlis   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

(2012) M. Faham et al.   BLOOD

Pathogenesis of Myeloma

(2011) Kenneth C. Anderson et al.   Annual Review of Pathology-Mechanisms of Disease

Plasma cell leukemia

(2011) Flavio Albarracin et al.   BLOOD REVIEWS

Genomics in Multiple Myeloma

(2011) Nikhil C. Munshi et al.   CLINICAL CANCER RESEARCH

Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

(2011) K. D. Boyd et al.   CLINICAL CANCER RESEARCH

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Adaptive clinical trials in oncology

(2011) Donald A. Berry   Nature Reviews Clinical Oncology

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma

(2009) L. Chen et al.   BLOOD

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE